Agilent Technologies Inc vs Hyatt Hotels Corporation — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Hyatt Hotels Corporation trades at $172.22 (market cap $16.03B). The key difference: Agilent Technologies Inc is far larger — about 2.6× Hyatt Hotels Corporation's market cap, and Agilent Technologies Inc pays the higher dividend (0.69%). Which is the better fit depends on your goals.
| A | H | |
|---|---|---|
Market Cap | $42.00B | $16.03B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $202.09 |
52-Week Low | $110.24 | $135.01 |
Enterprise Value | $43.55B | $19.93B |
Dividend Yield | 0.69% | 0.35% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Hyatt Hotels Corp (H) trades at $177.71, down 0.65% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings beats in Q2 2026 and a raised RevPAR outlook highlight operational momentum, but high valuation ratios and a negative net income in 2025 pose concerns. The stock is near its 52-week high of $206.86, with support at $176 and resistance at $180.
The outlook is cautious; while fee growth and travel demand support expansion, the stock's rich valuation and debt levels warrant patience. Risks include regional weakness and project delays. Analysts maintain a mixed consensus with a $201 price target, suggesting limited near-term upside amid balanced investor sentiment.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →